dr. davids on results of obinutuzumab with ibrutinib
Published 6 years ago • 220 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:34
dr. davids on the combination of ibrutinib and obinutuzumab in cll
-
1:09
dr. davids discusses the results of ibrutinib plus fcr in cll
-
1:36
dr. davids on cost effectiveness of time-limited therapy with venetoclax/obinutuzumab in cll
-
0:47
dr. davids on the potential utility of frontline ibrutinib/umbralisib in mcl and cll
-
1:22
dr. davids on updated data with ibrutinib/umbralisib in r/r cll and mcl
-
1:07
dr. davids on the potential utility of ibrutinib/umbralisib in mcl and cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:22
dr. davids on rationale for ibrutinib/umbralisib combo in r/r cll and mcl
-
0:53
dr. kambhampati on frontline ibrutinib plus obinutuzumab in cll
-
1:17
dr. davids on ibrutinib plus fcr in younger patients with cll
-
2:18
the combination of ibrutinib and obinutuzumab in cll
-
7:01
novel frontline combinations with ibrutinib in cll
-
0:54
dr. davids discusses ongoing research with ibrutinib plus venetoclax in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
1:14
dr. davids on exciting data with acalabrutinib in cll
-
0:59
dr. davids on frontline challenges in cll
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
1:25
dr. rogers discusses obinutuzumab, ibrutinib, and venetoclax combination in cll